Stairlifts Market: Foresees Skyrocketing Growth in the Coming Years Tamoxifen Market

Tamoxifen Market - Size, Share, Growth,
Outlook, and Opportunity Analysis, 2018-2026
Tamoxifen is a type of selective estrogen receptor modulator (SERM) indicated for the treatment of
women with high risk of breast cancer. Since its approval in 1998, tamoxifen has been used to treat
millions of patients diagnosed with hormone receptor positive, early stage of breast cancer after
surgery to reduce the risk of recurrence. It is the first choice for treatment of premenopausal women.
Tamoxifen is the generic name for Nolvadex. Tamoxifen has off-label usage for the treatment of
infertility, gynecomastia, retroperitoneal fibrosis, and idiopathic sclerosing mesenteritis.
Tamoxifen is a type of selective estrogen receptor modulator. The main pharmacologic action of
Tamoxifen is to block the growth-promoting efects of estrogens on breast cancer. In bone cells,
selective estrogen modulators interact with receptors the way estrogen does and strengthens
bones. Tamoxifen is available in various forms such as powder, capsules, oral solution, and
tablets.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1801
Tamoxifen Market – Regional Insights
On the basis of region, the global tamoxifen market is segmented into North America, Europe,
Latin America, Asia Pacifc, Middle East, and Africa. North America tamoxifen market holds the
dominant position, owing to high acceptance and high price of the drug in treating breast cancer.
For instance, according to GoodRx Inc. 2018 pricing detail, 30 tablets of tamoxifen 20mg cost
around US$ 65.71 on an average. Moreover, increasing prevalence of breast cancer has
propelled the tamoxifen market growth in the North America region. According to 2018, U.S.
Breast Cancer Organization statistics, around 1 in 8 U.S. women are estimated to develop
invasive breast cancer during the course of her life. Moreover, around 266,120 women are
expected to be diagnosed with invasive breast cancer in the U.S. in 2018.
Asia Pacifc is expected to witness signifcant growth in the market over the forecast period,
owing to its increasing number of people vulnerable to various chronic diseases and increasing
healthcare initiatives. For instance, according to published article in the Lancet Oncology 2014,